A small study suggests that changes in brain activity may be the cause of chemo brain.
Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.
About half of women diagnosed with early-stage triple-negative breast cancer who were not eligible for lumpectomy when first diagnosed became eligible for lumpectomy after neoadjuvant chemotherapy.
Two studies presented at the 2015 San Antonio Breast Cancer Symposium suggest that adding carboplatin to the standard neoadjuvant chemotherapy regimen may improve outcomes for women diagnosed with triple-negative disease.
Women diagnosed with early-stage, HER2-negative breast cancer with residual disease who were treated with Xeloda after surgery had better survival compared to women who didn't get chemotherapy after surgery.
A study has found that women diagnosed with inflammatory breast cancer who are treated with chemotherapy, surgery, and radiation have better survival rates than women who don't receive all three treatments.
Women diagnosed with breast cancer who were treated with chemotherapy had lower levels of immune system cells for at least 9 months after chemotherapy ended.
A study has found that women older than 80 diagnosed with early-stage, hormone-receptor-negative breast cancer don't get survival benefits from chemotherapy.
Researchers urge women who have had breast cancer treatment to keep their heart health in mind as they build long-term health.
In the GeparSixto study, women with a BRCA1 or BRCA2 mutation responded better to chemotherapy before surgery without carboplatin, while women without a mutation had better outcomes when carboplatin was added to the chemotherapy regimen.
Postmenopausal women diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive lymph nodes and an Oncotype DX Recurrence Score of 25 or lower being treated with hormonal therapy after surgery can safely skip chemotherapy.
The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.
Avastin combined with Taxol lengthens the time until advanced breast cancer progresses, but doesn't improve overall survival.
Getting Taxol (chemical name: placlitaxel) every week seems to have more benefits than getting it every 3 weeks or getting Taxotere (chemical name: docetaxel) on either schedule.
A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.
A small study shows that other factors besides breast cancer treatment contribute to bone loss in post-menopausal women.
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
The FDA is considering whether to continue the approval for using Avastin with Taxol to treat metastatic breast cancer, as well as whether to approve it in combination with other medicines.
Being older and having lower cognitive reserve levels may increase the risk of cognitive problems during and after chemotherapy.
Lower quality of life during and after breast cancer treatment seems to be closely linked to two factors: menopausal symptoms and chemotherapy side effects.
Research suggests that giving BOTH chemotherapy and radiation therapy before surgery to remove locally advanced breast cancer can help reduce the risk of the cancer coming back in the breast area in the 5 years after surgery.
A small, early study suggests that a combination of Herceptin and Taxol seemed to reduce the risk of recurrence of small HER2-positive breast cancers that hadn't spread to the lymph nodes.
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.